Relay Therapeutics, Inc.
FGFR INHIBITORS AND METHODS OF MAKING AND USING THE SAME

Abstract:

The disclosure is in part directed to crystalline forms of N-(4-(4-amino-5-(3-fluoro-4-(4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-- 7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide, its salts, its cocrystals, and variants thereof.